First US Implant of Vericel’s MACI

Vericel announced the first U.S. implant of MACI® autologous cultured chondrocytes for the treatment of symptomatic knee cartilage defects.

This closely follows the 4Q16 FDA approval of MACI, indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults....

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us